Method of hyperthemia treatment

Abstract

Magnetic nanoparticle compositions are provided which provide an inherent temperature regulator for use in magnetic heating, particularly for use in magnetic hyperthermia medical treatments. The composition includes magnetic nanoparticles having a Curie temperature of between 40 and 46° C., preferably about 42° C., and may further include a polymeric material and optionally a drug or radiosensitizing agent. Methods of hyperthermia treatment of a patient in need thereof are provided which include administering to the patient a composition comprising magnetic nanoparticles having a Curie temperature of between 40 and 46° C.; and exposing the magnetic nanoparticles in the patient to an alternating magnetic field effective to generate hysteresis heat in the nanoparticles.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a divisional of U.S. patent application Ser. No. 11 / 125,488, filed May 10, 2005, which claims the benefit of U.S. Provisional Application No. 60 / 569,726, filed May 10, 2004. The applications are incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION[0002]This invention relates generally to magnetic nanoparticle compositions, and more particularly to magnetic nanoparticle compositions useful in self-controlled hyperthermia treatment.[0003]Diseases of the human body such as malignant tumors are generally treated by excision, chemotherapy, radiotherapy or a combination of these approaches. Each approach has limitations affecting it clinical utility. For example, excision may not be appropriate where the disease presents as a diffuse mass or is in a surgically inoperable location. Chemotherapeutic agents are generally non-specific, thus resulting in the death of both normal and diseased cells. Radioth...

AI Technical Summary

Problems solved by technology

Each approach has limitations affecting it clinical utility.

For example, excision may not be appropriate where the disease presents as a diffuse mass or is in a surgically inoperable location.

Chemotherapeutic agents are generally non-specific, thus resulting in the death of both normal and diseased cells.

Radiotherapy is also nonspecific and results in the death of normal tissues exposed to ionizing radiation.

It has been reported that when heat and a radiosensitizing agent (e.g., misonidazole) are used in combination with each other, they produce synergistic potentiation effects.

However, Hofer's whole body heating approach is not optimal for clinical application on human, because whole-body heating limits the heat dose that can be given.

Limitations of these methods are due either to the invasive thermometry or in their inability to reach optimal temperature for the tumor sites when noninvasive techniques are used, especially in the treatment of deep-seated tumors.

However, at least two impediments to clinical implementation have been identified: (1) the lack of uniform heat distribution at the tumor site and the resultant creation of spot overheating that leads to necrosis; and (2) the size of these thermoseed particles are on the order of 1 to 5 cm, making them highly non-biocompatible.

Unfortunately, conventional magnetic particles make it impossible to control the uneven heating at the tumor site, which may cause local overheating and necrosis of healthy tissue.

Images